CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Conditions:  Advanced Biliary Tract Carcinoma;  Advanced Colorectal Carcinoma;  Advanced Gastroesophageal Junction Adenocarcinoma;  Advanced Lung Adenocarcinoma;  Advanced Malignant Solid Neoplasm;  Advanced Ovarian Carcinoma;  Advanced Pancreatic Carcinoma;  Advanced Urotheli al Carcinoma;  Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;  Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;  Metastatic Biliary Tract Carcinoma;  Metastatic Colorectal Carcinoma;  Metastatic Gastroesophageal Junction Adenocarcinoma;  Met astatic Lung Adenocarcinoma;  Metastatic Ovarian Carcinoma;  Metastatic Pancreatic Carcinoma;  Metastatic Urothelial Carcinoma;  Refractory Biliary Tract Carcinoma;  Refractory Colorectal Carcinoma;  Refractory Gastroesophageal Junction Adenocarcinoma;  Refractory Lung A denocarcinoma;  Refractory Ovarian Carcinoma;  Refractory Pancreatic Carcinoma;  Refractory Urothelial Carcinoma;  Stage II Pancreatic Cancer AJCC v8;  Stage III Colorectal Cancer AJCC v8;  Stage III Lung Cancer AJCC v8;  Stage III Ovarian Cancer AJCC v8;  S tage III Pancreatic Cancer AJCC v8;  Stage IV Colorectal Cancer AJCC v8;  Stage IV Lung Cancer AJCC v8;  Stage IV Ovarian Cancer AJCC v8;  Stage IV Pancreatic Cancer AJCC v8 Interventions:  Procedure: Biospecimen Collection;  Procedure: Computed...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Gastroenterology | Hydroxychloroquine | Research